Treatment Options for Hyponatremia in Heart Failure
Article first published online: 23 JUL 2010
© 2010 Wiley Periodicals, Inc.
Congestive Heart Failure
Special Issue: Volume Overload, Renal Function, and Heart Failure: Diagnostic and Management Strategies
Volume 16, Issue Supplement s1, pages S15–S18, July/August 2010
How to Cite
Goldsmith, S. R. (2010), Treatment Options for Hyponatremia in Heart Failure. Congestive Heart Failure, 16: S15–S18. doi: 10.1111/j.1751-7133.2010.00164.x
- Issue published online: 23 JUL 2010
- Article first published online: 23 JUL 2010
- Manuscript received April 13, 2010; accepted April 25, 2010
Hyponatremia is independently associated with adverse outcomes in patients with congestive heart failure (CHF). The primary cause of hyponatremia in CHF is the inappropriate secretion of the antidiuretic hormone arginine vasopressin (AVP). The binding of AVP to V2 receptors in the renal collecting duct promotes water retention, a process that can lead to dilutional hyponatremia as well as increased ventricular preload. Conventional treatment of hyponatremia in CHF is largely based on water restriction, which is neither effective nor well-tolerated. V2- and dual V1a/V2-receptor antagonists offer physiologically based treatment for dilutional hyponatremia. Clinical trials in patients with hyponatremia including those with CHF using both selective and nonselective vasopressin antagonists have demonstrated the effectiveness and safety of these agents in correcting this common electrolyte abnormality. Congest Heart Fail. 2010;16(4)(suppl 1):S15–S18. ©2010 Wiley Periodicals, Inc.